Skip to content

Study · Not a test of the peptide alone · 2024

5 results

Comprehensive Analysis of Kisspeptin Signaling: Effects on Cellular Dynamics in Cervical Cancer.

Rodríguez-Sarmiento DY, Rondón-Villarreal P, Scarpelli-Pereira PH, Bouvier M

Biomolecules29 Jul 2024Cited by 2 (Europe PMC)

PMID39199311 (opens in a new tab)PMCIDPMC11352469 (opens in a new tab)DOI10.3390/biom14080923 (opens in a new tab)PepBankPUB-39199311
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Kisspeptin, a key neuropeptide derived from the KISS1R gene, is renowned for its critical role in regulating the hypothalamic-pituitary-gonadal axis and reproductive hormone secretion. Beyond its primary function in reproductive biology, emerging research has illuminated its influence in various cancers, mediating significant effects through its interaction with the G protein-coupled receptor, kisspeptin receptor. This interaction has been implicated in modulating cellular processes such as proliferation and metastasis, making it a potential target for therapeutic intervention. Our study initially screened ten kisspeptin-10 analogs through cytotoxic effects of kisspeptin-10 (KP10) and its analogs in several cancer types, including cervical, prostate, breast, and gastric cancers, with a particular focus on cervical cancer, where the most profound effects were observed. Further exploration using kinase array assays revealed that these analogs specifically alter key kinases involved in cancer progression. Migration assays demonstrated a substantial decrease in cell motility, and Bioluminescence Resonance Energy Transfer assays confirmed these analogs' strong interactions with the kisspeptin receptor. Overall, our results indicate that these KP10 analogs not only hinder cervical cancer cell proliferation but also curtail migration through targeted modulation of kinase signaling, suggesting their potential as therapeutic agents in managing cervical cancer progression. This comprehensive approach underscores the therapeutic promise of exploiting kisspeptin signaling in cancer treatment strategies.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 01LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Activity measurement

    In cancer cell screens, ten kisspeptin‑10 analogs showed cytotoxic effects, strongest in cervical cancer.

    In plain wordsIn lab tests, kisspeptin‑10 analogs were toxic to cancer cells, most of all cervical cancer cells.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseCytotoxic effects of KP10 analogs in cancer cells
    Study

    n: not reported in source

    Cervical, prostate, breast and gastric cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Our study initially screened ten kisspeptin-10 analogs through cytotoxic effects of kisspeptin-10 (KP10) and its analogs in several cancer types, including cervical, prostate, breast, and gastric cancers, with a particular focus on cervical cancer, where the most profound effects were observed.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  2. 02LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Mechanism

    In kinase array assays, KP10 analogs altered key kinases involved in cancer progression.

    In plain wordsIn lab tests, kisspeptin‑10 analogs changed key proteins linked to cancer growth.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableKinase changes with KP10 analogs
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Further exploration using kinase array assays revealed that these analogs specifically alter key kinases involved in cancer progression.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  3. 03LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Efficacy outcome

    In migration assays, KP10 analogs substantially decreased cell motility.

    In plain wordsIn lab tests, kisspeptin‑10 analogs strongly reduced cell movement.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseCell motility in migration assays
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Migration assays demonstrated a substantial decrease in cell motility, and Bioluminescence Resonance Energy Transfer assays confirmed these analogs' strong interactions with the kisspeptin receptor.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  4. 04LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Activity measurement

    Bioluminescence Resonance Energy Transfer assays confirmed strong interactions of the KP10 analogs with the kisspeptin receptor.

    In plain wordsIn lab tests, kisspeptin‑10 analogs bound strongly to the kisspeptin receptor.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableAnalog interaction with the kisspeptin receptor (BRET)
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Migration assays demonstrated a substantial decrease in cell motility, and Bioluminescence Resonance Energy Transfer assays confirmed these analogs' strong interactions with the kisspeptin receptor.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  5. 05LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Efficacy outcome

    In cervical cancer cells, KP10 analogs hindered cell proliferation.

    In plain wordsIn lab tests, kisspeptin‑10 analogs slowed the growth of cervical cancer cells.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseCervical cancer cell proliferation
    Study

    n: not reported in source

    Cervical cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    these KP10 analogs not only hinder cervical cancer cell proliferation but also curtail migration through targeted modulation of kinase signaling, suggesting their potential as therapeutic agents in managing cervical cancer progression.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.